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AlpersMitochondrial DNA polymerase, POLG, is the sole DNA polymerase found in animal mitochondria. In humans,
POLGα W748S in cis with an E1143G mutation has been linked to a new type of recessive ataxia, MIRAS,
which is the most common inherited ataxia in Finland. We investigated the biochemical phenotypes of the
W748S amino acid change, using recombinant human POLG. We measured processive and non-processive
DNA polymerase activity, DNA binding afﬁnity, enzyme processivity, and subunit interaction with recom-
binant POLGβ. In addition, we studied the effects of the W748S and E1143G mutations in primary human cell
cultures using retroviral transduction. Here, we examined cell viability, mitochondrial DNA copy number,
and products of mitochondrial translation. Our results indicate that the W748S mutant POLGα does not
exhibit a clear biochemical phenotype, making it indistinguishable from wild type POLGα and as such, fail to
replicate previously published results. Furthermore, results from the cell models were concurrent with the
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The minimal mitochondrial DNA (mtDNA) replisome comprises
the mitochondrial DNA polymerase (POLG) [1], helicase (Twinkle) [2]
and mitochondrial single-stranded DNA-binding protein (mtSSB)
[3,4]. Of the 16 knownmammalian DNA polymerases, POLG is the only
one found in animal mitochondria, making it solely responsible for
replication and repair of mtDNA. In mammals, the functional POLG
holoenzyme is a heterotrimer, which consists of one catalytic subunit
(POLGα) and an accessory subunit dimer (POLGβ) [5,6].
The catalytic subunit POLGα contains DNA polymerase and exo-
nuclease domains that are separated by a spacer region. The spacer
region contains four conserved DNA sequence blocks (γ1–γ4). In
recent studies the spacer region has been established to play a role in
DNA template binding and positioning, and in interaction with theaccessory subunit dimer POLGβ and likely mtSSB [7]. Mutations in the
human POLGα spacer region have been linked to wide a variety of
inherited neurodegenerative phenotypes, such as ataxia, infantile
Alpers syndrome and sensory ataxic neuropathy [8–11]. We and col-
laborators have reported a new neurodegenerative disorder with
autosomal recessive ataxia, mitochondrial recessive ataxia syndrome
(MIRAS) [10,12,13]. In fact among all neurological diseases caused by
mutations in POLGα, the most severe manifestations are caused by
mutations in the spacer region in combination with polymorphisms
and mutations in the DNA polymerase domain, which affect the
central nervous system and sometimes also the liver.
MIRAS is caused by two amino acid changes in POLGα: W748S in
cis with E1143G. W748 is located in the conserved γ4 region within
the spacer domain, whereas E1143 localizes to the conserved pol C
region in the polymerase domain. This allele is the most common
genetic cause of inherited ataxia in Finland, with a carrier frequency
of 1:125. The MIRAS allele is also found in patients from Australia,
Norway and New Zealand [14]. MIRAS exhibits a wide variety of
clinical features, resembling other ataxias caused by mitochondrial
dysfunction (Friedrich's Ataxia, IOSCA) [15–17]. The age of onset
varies from 5 to 50 years and the patients have ataxia and cerebellar
dysarthria, which are also present in other mitochondrial ataxias.
Symptoms that are not frequently present in MIRAS patients, such as
muscle weakness and pes cavus (highly arched foot), distinguish
MIRAS from other mitochondrial ataxias [12]. MIRAS patients exhibit
tissue-speciﬁc reduced mtDNA levels, and mtDNA deletions in brain
and liver. In addition, the patients exhibit a clear cell-speciﬁc
Fig. 1. Puriﬁed human POLGα protein. Recombinant wild type (lane 1, 100 ng; lane 2,
200 ng) and W748S mutant of human POLGα protein (lane 3, 100 ng; lane 4, 200 ng).
Silver stained 10% SDS–PAGE gel. The size of the puriﬁedmutant protein was compared
to the previously puriﬁed wild type enzyme. No difference in the stability of the mutant
enzyme was detected in the puriﬁcation procedure, compared to the wild type.
Table 1
Biochemical properties of wild type and mutant forms of human POLG.
Wild type
POLGα
W748S
mutant
POLGα
*A467T
mutant
POLGα
Speciﬁc activity (units/mg)
Gapped double-stranded DNA 8100–9300 7200–26,000 3900
Poly r(A)-oligo d(T) 712±121 852±209
Singly primed M13 DNA 123±14 143±17
Km (μM dNTP)
Gapped double-stranded DNA 66.1±6.3 66.5±4.8
Singly primed M13 DNA 0.77±0.07 0.75±0.06
Average processive unit (nt)
POLGα 52.8±13.6 48.2±12.7 55.8±13.4
POLG holoenzyme 245±34.0 257±32.8 144±26.9
DNA binding afﬁnity, Kd (nM) 6.8±0.37 11.1±0.52
* The A467T mutant POLGα was used as a control mutant enzyme (see [20]).
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[17]. However, when based solely on the clinical features, MIRAS is
indistinguishable from other spinocerebellar ataxias. Therefore, the
diagnosis must be based on molecular genetic analysis.
The biochemical effects of speciﬁc POLGα spacer region mutations
have been investigated with recombinant D. melanogaster and
human POLGα [7,18–20]. A deletion of the conserved γ4 region in
D. melanogaster POLGα weakens the interaction with POLGβ and
decreases DNA polymerase activity [7]. We and others have reported
that a mutation A467T in POLGα that maps to the conserved γ1 region
causes low DNA polymerase activity, diminished interaction with
POLGβ, and decreased processivity of the enzyme. Another spacer
region mutant, R627Q/W, exhibits normal DNA polymerase activity,
and slightly higher DNA binding capacity and processivity [20]. Pre-
viously, Chan et al. have reported that the W748S amino acid sub-
stitution results in low DNA polymerase activity, DNA binding and
slightly reduced processivity, and that all of these defects are rescued
partially when W748S is present in cis with common variant E1143G
[19]. These diverse results establish clearly that mutations in the
spacer region of the POLGα do not cause any uniform biochemical
phenotype.
The phenotype of the patients who are homozygous for W748S
in cis with E1143G varies greatly, ranging from late-onset polyneuro-
pathy to acute encephalopathy in adolescence [10,11,21,22]. This
ﬁnding suggests a considerable role for modifying factors in the se-
verity of the disease manifestation. Given the varying clinical pheno-
type of MIRAS and diverse biochemical phenotypes of other spacer
region mutants, we asked if a rigorous biochemical characteriza-
tion of recombinant human POLGα carrying a W748S amino acid
substitution could provide a new insight into the pathogenesis of
MIRAS, and verify previously published results. Because POLG has the
highest polymerase activity on templates with high primer density,
we used both natural and synthetic sequence DNA templates with low
and high primer density to measure processive and non-processive
DNA synthesis [1]. We also measured DNA binding and subunit
interactions.
Studies on the biochemical properties of the puriﬁed POLGαW748S
protein suggest that the mechanisms underlying MIRAS are not
explained solely by a catalytic enzyme defect. We extended these
studies to examine primary cells transduced with retroviruses carrying
W748S, E1143G, W748S+E1143G or wild type transgenes. Expression
levels of transduced POLGαweremeasured by quantitative RT-PCR and,
relative mtDNA amounts by quantitative PCR. Pulse labeling of
mitochondrial translation products was used to study possible effects
on mitochondrial translation efﬁciency.
2. Results
2.1. Overexpression and puriﬁcation of W748S mutant POLGα
We expressed and puriﬁed recombinant proteins carrying either
wild-type or W748S POLGα, using the baculovirus overexpression
system. The exonuclease activity of both of the recombinant poly-
merases was eliminated by substitution of two catalytic aspartates for
alanine in the exonuclease I motif, as described previously [23]. Both
catalytic cores were expressed and subjected to two independent
puriﬁcations, and all experiments were performed with enzyme from
both preparations. In all puriﬁcations, approximately 2.2 l of Sf9 insect
cells were infected with baculoviruses carrying the exonuclease-
deﬁcient human POLGα cDNA, and the recombinant proteins were
puriﬁed 180-fold, to near homogeneity. About 0.6 mg of recombinant
protein was puriﬁed per liter of infected cells, with a ﬁnal yield of 6%.
We found no signs of structural variation or instability in the mutant
enzyme, based on chromatographic proﬁles and peaks in velocity
sedimentation. All of the ﬁnal preparations were of similar purity
(Fig. 1).2.2. Functional analysis of the recombinantW748Smutant POLGα enzyme
We measured the intrinsic DNA polymerase activity of the
W748S mutant POLGα catalytic core by examining non-processive
and processive polymerase activity. Non-processive DNA polymerase
activity was measured using a gapped, double-stranded natural se-
quence DNA substrate with high primer density, DNase I-activated
calf thymus DNA. Speciﬁc activities obtained under conditions of
substrate excess were 8100–9300 U/mg for the wild-type human
POLGα used as control, and 7200–26,000 U/mg for the W748S
mutant POLGα. Steady state kinetic analysis of DNA synthesis activity
on this substrate in comparisonwith thewild-type enzyme yielded no
signiﬁcant differences; the Km values were 66.1 µM for wild type and
66.5 µM for W748S mutant POLGα enzyme (Table 1).
Next we evaluated processive DNA polymerase activity with both
natural and synthetic DNA substrates. We used singly primed M13
DNA as the natural sequence DNA substrate, and under conditions of
substrate excess the speciﬁc activities were 123 and 143 U/mg for
wild type and W748S mutant, respectively. Likewise, we found no
differences when we used the POLG-speciﬁc synthetic substrate poly
(rA)·oligo(dT) as template-primer. Here speciﬁc activities were 712
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(Table 1).
We evaluated enzyme processivity directly by analyzing DNA
product strand length by denaturing gel electrophoresis under condi-
tions of large substrate excess, such that the association–dissociation
cycle was limited to once per enzyme molecule, and then calculated
the average processive unit. Both wild type and W748S mutant
POLGα showed similar processivities with average processive units of
52.8 and 48.2 nt, respectively (Fig. 2, Table 1).
2.3. Processive DNA polymerase activity of recombinant POLGholoenzymes
Though we observed no differences in the activities of the wild
type and mutant catalytic cores, we evaluated possible defects in the
POLG holoenzymes by reconstitution with the accessory subunit,
POLGβ. We measured processive DNA synthesis on singly primed
M13DNA at 100 mM KCl using the POLG holoenzyme reconstituted
either with the wild type or the mutant catalytic core, in the presence
of a 4-fold excess (as monomer) of the wild type POLGβ. We obtained
similar Km values of 0.77 µM for the wild type and 0.75 µM for the
W748S mutant (Table 1).
Products of processive DNA synthesis were also analysed as
with the catalytic cores, except that the reaction conditions were
optimized for POLG holoenzyme activity in the presence and absence
of a 4-fold excess of wild type POLGβ as monomer. POLG holo-Fig. 2. Processivity of mutant and wild type human POLGα subunit. DNA synthesis by
mutant POLGαwas measured at 30 mM KCl on singly primed M13 DNA as described in
Materials and methods. DNA product strands were isolated, denatured and electro-
phoresed as duplicates in a 6% denaturing polyacrylamide gel. Lanes 1 and 2, wild type
POLGα; lanes 3 and 4, W748S mutant POLGα. Size marker: NEB 2-log DNA-ladder
(molecular weights shown). The processivity of the mutant catalytic core enzyme was
similar to the wild type enzyme.enzyme processivities were similar, with average processive units of
245 and 258 nt for the wild type and mutant enzymes, respectively
(Fig. 3, Table 1).
2.4. DNA binding afﬁnity of W748S mutant POLG holoenzyme
We examined the DNA-binding afﬁnity of W748S POLGα using a
quantitative gel electrophoretic mobility-shift assay (EMSA) with a
21/45-mer DNA as a primer-template. The DNA-binding afﬁnity
was measured with and without wild type POLGβ, at 100 or 30 mM
KCl, respectively. Reconstituted mutant POLG holoenzyme showed
slightly reduced DNA binding, with a Kd value of 11.1 nM as compared
to 6.8 nM for wild type POLG holoenzyme (Table 1).
2.5. Effect of W748S in cis with E1143G mutant POLGα overexpression in
cells
We subcloned a human POLGα cDNA with or without mutations
W748S and E1143G into a retroviral vector. When introduced into
the host cell genome, the retroviral vectors induced a high level of
overexpressionofPOLGα, conﬁrmedwithquantitativeRT-PCR tobe7–19
fold higher as compared to endogenous expression levels (data notFig. 3. Processivity of reconstituted mutant and wild type POLG holoenzyme. Human
POLG was reconstituted using a 4-fold molar excess of the accessory POLGβ subunit
over POLGα, and DNA synthesis was measured at 100 mM KCl on singly primed M13
DNA. DNA product strands were isolated, denatured and electrophoresed in denaturing
1.5% agarose (upper panel) and 6% polyacrylamide (lower panel) gels. Wild type
POLGα in the absence (lane 1) and presence (lane 2) of POLGβ, lanes 3 and 4, W748S
mutant of POLGα in the absence (lane 3) and presence (lane 4) of POLGβ, A467T
mutant of POLGα in the absence (lane 5) and presence (lane 6) of POLGβ. Size marker:
NEB 2-log DNA-ladder (molecular weights shown). As reported previously, the A467T
mutant enzyme produced low-molecular-weight products similar to wild type, but not
longer products [20]. However, the W748S enzyme processivity was similar to wild
type also concerning the longest products.
Fig. 4. Three-dimensional structural model of the catalytic subunit of human POLGwith
docked DNA template. Locations of ataxia-mutants R627, W748 and E1143 within the
catalytic subunit of human POLGα are indicated relative to DNA docked into the
structure (Protein Data Bank entry 3IKM, chain A [24]). The ﬁgure was prepared using
the Visual Molecular Dynamics software (VMD) [33].
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the mtDNA helicase, which was not affected by overexpression of the
mutant or wild type POLGα. Likewise, no changes in relative mtDNA
levels were detected, nor was mitochondrial translation affected by
mutant or wild type POLGα overexpression, as measured by pulse
labeling of mitochondrial proteins (data not shown).
2.6. Predicted structural consequences of POLGα amino acid changes
We utilized the recently published structure of human POLGα [24]
to generate a modeled complex with docked template DNA (Fig. 4).
We identiﬁed the relevant amino acids W748, R627 and E1143 in our
model and marked them for clarity. W748 and R627 are both located
in the IP-domain of the spacer region, not in direct contact with DNA.
Notably, the E1143 residue locates to a different domain of POLGα;
the distance between W748 and E1143 is ∼61.5 Å.
3. Discussion
Spacer region mutations of POLGα result typically in recessive
nervous system disorders, whereas catalytic sitemutations cause domi-
nant myopathies in addition to neuronal defects [20,25]. The basis for
the tissue-speciﬁcity is unknown.We investigatedherewhether altered
biochemical activities of the enzyme could explain some of the tissue-
speciﬁcﬁndings. The spacer region of human POLGαparticipates in DNA
template positioning and in subunit interactions [18,20]. Furthermore,
in D. melanogaster, the spacer region has been shown to affect
processivity and to interact functionally with mitochondrial single-
strand DNA-binding protein [7]. Our results indicate that similar to
another ataxia mutation, R627Q/W, theW748Smutationwhich causes
MIRAS-ataxia, does not affect the catalytic activity of POLGα. These
results suggest that ataxia-associated spacer regionmutations of POLGα
manifest in a highly tissue-speciﬁc context.
We puriﬁed recombinant W748S mutant POLGα twice in indepen-
dent puriﬁcations, and did not ﬁnd signs of structural instability
or variability. Our initial measurements of speciﬁc DNA polymerase
activity on three substrates, partially degraded DNAse I-activated calf
thymus DNA, poly (rA)·oligo(dT) and singly primedM13DNA, failed to
reveal differences between the W748S mutant and wild type POLGα.
This prompted us to study the DNA polymerase activity further using
steady-state kinetics on the DNAse I-activated DNA substrate, yet again
we observed no difference between the wild type or W748S mutant
enzyme, thus corroborating our initial data. In contrast, Chan et al. have
reported that the W748S mutant POLGα has only 2.3% of wild type
POLGα polymerase activity using poly(rA)·oligo(dT) template-primer
as a substrate [19]. At the same time, with regard to the A467T mutant
POLGα, our results agree with those of Chan et al.; both laboratories
have shown a clear reduction of DNA polymerase activity [18,20]. In the
case of the W748S mutation, we feel that an artifactual gain of mutant
enzyme activity is unlikely; rather, we show clearly that the presence of
the W748S substitution in the POLGα polypeptide does not affect the
catalytic properties of the enzyme.
One of the major ﬁndings in the studies on A467T mutant POLGα
was that the interaction between the catalytic core and accessory
subunit is affected [18,20]. This prompted us to evaluate a possible
defect in subunit interactions in W748S mutant POLGα using steady
state kinetic assays. Our results indicate that the W748S mutant
POLGα is stimulated by wild type POLGβ in the same fashion as wild
type POLGα, arguing strongly that subunit interaction is not affected
by the W748S POLGαmutation. These results are consistent with the
earlier study, which shows that the subunit interaction of W748S
mutant POLGα with the accessory subunit is similar to that of wild
type POLGα [19].
The accessory subunit of POLG contributes to DNA polymerase
activity of the holoenzyme, as well as to DNA binding by allowing it to
bind its substrates more tightly [5]. We studied the ability of W748Smutant and wild type POLG holoenzyme to bind DNA using an
electrophoreticmobility shift assay.W748Smutant POLG holoenzyme
shows a 1.6-fold reduction in DNA binding as compared to wild type
POLG holoenzyme. The DNA binding ability of W748S mutant POLGα
was also studied by Chan et al., who reported that the W748S muta-
tion caused an 8-fold decrease in DNA binding by the catalytic core
alone [19]. Together these results might suggest that impairment of
the DNA binding capability of W748S mutant POLGα is compensated
in the POLG holoenzyme by its interaction with POLGβ. However, we
ﬁnd it unlikely, because we found that enzyme processivity was not
affected by the W748S amino acid change regardless of the presence
or absence of POLGβ. Because processivity is inﬂuenced by both
DNA binding ability and polymerase activity [1], and neither
W748S mutant POLGα nor its reconstituted holoenzyme exhibit
lower processivity as compared to the wild type forms, we conclude
that the small decrease we observe in the DNA binding ability of
the W748S mutant POLG holoenzyme is apparently irrelevant for
processivity of the POLG holoenzyme. In contrast, Chan et al. reported
that the W748S mutant POLGα core and the mutant holoenzyme
processivities are impaired as compared to the wild type forms, and
conclude that this impairment is caused by the weak DNA binding
and low polymerase activity of W748S mutant POLGα [19]. POLGβ
stimulates the processivity of wild type POLGα as much as 50-fold, to
a value over 1000 nt, mainly by increasing DNA binding afﬁnity [1,6].
Our current data show stimulation that results in products up to 3 kb
and the discrepancy between the processivity analyses in the two
reports might relate to the fact that Chan et al. visualized products up
to 200 nt, not taking into account the expected effect of the accessory
subunit [19].
After submission of our manuscript, Lee et al. published the three-
dimensional structure of human POLG [24]. Their structure shows that
theW748 residue is located in the IP-region of the spacer, and that the
ataxia-associated R627Q/Rmutant is also located in the same domain.
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phenotype [20]. Though the IP region contacts both DNA and the
catalytic domain, the R627 and W748 residues do not. Thus, the
mutations may cause local changes in the structure of the catalytic
subunit that might affect DNA ﬁnding. As proposed by Lee et al., the
W748 residue is likely involved in stacking interactions with H733
and F750 that maintain the conformation of the part of the IP domain
that is in contact with single-stranded DNA. This interpretation
warrants further experimentation because the crystals do not contain
a bound DNA template. Nonetheless, our results support an
interpretation of indirect interaction with DNA, as we observed
slightly lower DNA binding in the W748S mutant holoenzyme, which
did not, however, affect the processivity of the holoenzyme. Our data
suggest that the spacer IP domainmutants manifest in a highly tissue-
speciﬁc context, mainly in the nervous system.
In patients, the W748S amino acid change is always found in cis
with an E1143G polymorphic variant. This can be explained either by
a functional role of the variant or by a single ancestral chromosome, in
which the two mutations happened to occur. Barufﬁni et al. reported
that in S. cerevisiae, POLGα with and E1143G mutation showed low
protein levels, probably because of decreased stability, which likely
resulted in reduced DNA polymerase activity [26]. The actual POLGα
protein level in patients has not been reliably measured, mainly
due to poorly speciﬁc antibodies (commercial and private, unpub-
lished observations) and to low endogenous protein levels. We have
previously shown that W748S+E1143G occurred in a single ances-
tral chromosome, and therefore all MIRAS patients with W748S +
E1143G are distantly related [12,27]. In our structural model, we show
that E1143 locates to a different domain of POLGα with a distance of
∼61.5 Å to W748, and no direct interaction between the two amino
acids can be predicted. These data together with human genealogical
data do not suggest a speciﬁc role for the E1143G variant, but an
independent role in protein stability cannot be excluded.
Our aim in this study was to investigate whether the biochemical
phenotype ofW748Smutant POLGα could explain the drastic clinical
phenotype seen in MIRAS patients. The failure to identify any sub-
stantial differences between the mutant and wild type enzymes
in processive or non-processive DNA synthesis on several different
DNA templates establishes that the disease is not caused by a global
DNA synthetic defect. Further, cell lines highly overexpressing
POLGα W748S or W748S+E1143G protein exhibited no changes,
either in the level or integrity of the mtDNA nor in translation
of mitochondrial proteins. The lack of a catalytic defect appears to
be a common feature of nervous system phenotypes caused by
POLGα spacer mutations (including R627Q/W and W748S) [12,17].
Mutations in the mitochondrial replicative helicase Twinkle, a direct
functional partner of POLG, underlie the recessively inherited
infantile-onset spinocerebellar ataxia, IOSCA, which manifests at an
early age, strictly in the nervous system [28]. Interestingly, the IOSCA
mutant enzyme also exhibits normal in vitro activities [17]. These
ﬁndings emphasize that the neurons affected in MIRAS and IOSCA
depend on cell-speciﬁc mtDNA maintenance mechanisms, in which
the POLGα spacer plays an important role. These may involve tissue-
speciﬁc protein interactions, and/or effects of mtDNA organization
or segregation.
4. Materials and methods
4.1. Construction of recombinant baculoviruses
Baculovirus transfer vectors carrying mutant POLGα cDNAs de-
scribed were prepared by QuikChange mutagenesis with Pfu DNA
polymerase (Stratagene), according to the manufacturer's recom-
mendations and as described previously [12,29]. The following primer
pairs were used 5′-CTG GCT GCT CGT TTT TCA AGC TTC CTC ACA AG-3′
and 5′-CTT GTG AGG AAG CTT GAA AAA CGA GCA GCC AG-3′. Transfervectors encoding the mutant versions of POLGα were puriﬁed and
baculoviruses prepared as described by Wang and Kaguni [29].
4.2. Production and puriﬁcation of the recombinant POLGα subunit
The puriﬁcation of POLGα was done as described previously [20].
4.3. DNA polymerase assays
DNA polymerase activity was assayed on DNase I-activated
calf thymus DNA, singly primed M13 DNA or poly r(A)·oligo d(T)
as previously described [30,31]. Assays were performed at least
two times, in duplicate. Steady-state kinetic values were deter-
mined with either 5–400 nM DNase I-activated calf thymus DNA or
0.125–8 µM singly primedM13 DNA, with or without added 100 mM
KCl. Poly r(A)·oligo d(T) assays were done with 0.4 mM MnCl2
instead of MgCl2, 100 µM poly r(A)·oligo d(T) and 20 µM dTTP.
In stimulation assays 4-fold excess of wild type POLGβ was added
to reaction mixtures. Km values were determined using Origin 7.5
software (OriginLab). One unit of standard activity is that amount of
protein that catalyzes the incorporation of 1 nmol of deoxynucleo-
side triphosphate into acid insoluble material in 60 min at 30 °C
using DNase I-activated calf thymus DNA as the substrate.
4.4. Gel electrophoretic mobility-shift assay
DNA binding afﬁnity was assayed by a quantitative gel electro-
phoretic mobility-shift assay, as described previously [5], with the
followingmodiﬁcations: the amounts of POLGαwere 9–576 nmol, and
POLGβ was added in 4-fold molar excess over POLGα, as in other
assays. The datawere analyzed by scanning the Phosphor Screen using
the Typhoon 9400 phosphorimager (GE Healthcare, Piscataway, NJ),
and the volume of each bandwas determined by computer integration
analysis using ImageQuant version 5.2 software (GE Healthcare).
Kd valueswere determined usingOrigin 7.5 software (OriginLab), from
the fraction of DNA bound, samples derived from at least two inde-
pendent experiments.
4.5. Analysis of products of processive DNA synthesis by gel electrophoresis
Processivity of the POLG enzymes was measured as described
previously [5], but with the following modiﬁcations: 10 µM singly
primedM13 DNA, and 20 ng (0.14 pmol) of POLGαwas used in assays
and human POLGβ was added in 4-fold excess (0.56 pmol) over
POLGα. The data were analyzed by scanning the Phosphor Screen
using the Typhoon 9400 phosphorimager (GE Healthcare), and the
density of distinct bands from duplicate samples was determined by
computer integration analysis using ImageQuant version 5.2 software
(GE Healthcare); the density of the bands was normalized to the
nucleotide level to correct for the uniform labeling of the DNA
products, and the resulting DNA product strand lengths are presented
as apu (in nt) in Table 1.
4.6. Generation of POLG retroviral vectors with and without mutation(s)
The cDNA of human POLGα cloned in pcDNATM 3.1/myc-His A
was a kind gift from Docent JN Spelbrink. The cDNA of human
POLGα was mutagenized by PCR site-directed mutagenesis with
primer pairs
1 5′-CCCTGGCTGCTCGTTTTTCAAGCTGCCTCAC-3′,
2 5′-GTGAGGCAGCTTGAAAAACGAGCAGCCAGG-3′ and
3 5′-CGCTACCTGGTGCGGGGGGAGGACCGCTACCG-3′,
4 5′-CGGTAGCGGTCCTCCCCCCGCACCAGGTAGCG-3′
to produce nucleotide changes G2243C with primers 1 and 2 and
A3428G with primers 3 and 4 for W748S and E1143G, respectively.
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were 28.8–60 ng of template plasmid DNAs, 1 U of Phusion High
ﬁdelity DNA polymerase (Finnzymes), 20 µM of primers 1 and 2 or 3
and 4 (Sigma-Proligo), 200 µM of dNTP mix (Roche Diagnostics
GmbH), 3% of dimethyl sulfoxide (Roche Diagnostics GmbH) in 50 µl
of 1× Phusion HF buffer. Two step PCR ampliﬁcation was as follows:
primary denaturation at 99 °C for 30 s, denaturation at 99 °C for 10 s,
annealing and extension at 70 °C or 72 °C for 8 min for W748S and
E1143G mutations respectively and the ﬁnal extension at 72 °C for
10 min. Denaturation and annealing/extension steps were repeated
for 30 times. Mutated PCR products were puriﬁed from parental
template with DpnI restriction endonuclease (New England Biolabs).
Inserts POLGα, POLGα W748S, POLGα E1143G and POLGα W748S/
E1143G were digested from 30 µg of plasmid in double digestion
reactions with EcoRI and BamHI restriction endonucleases in EcoRI
buffer (Fermentas). The digested DNA pieces were gel puriﬁed with
QIAquick Gel Extraction Kit (Qiagen). To form blunt ends the
puriﬁed inserts were incubated with 36 µM dNTP mix and 1 U/ µg of
DNA of DNA Polymerase I large (Klenow) fragment in NEBuffer 2
(New England Biolabs). Samples were incubated at 25 °C for 15 min
after which they were gel puriﬁed. 30 µg of pBABEpuro vector was
digested with 0.5 U/ 1 µg of plasmid DNA of SnaBI restriction
enzyme (New England Biolabs) with 1 µg/ml of bovine serum
albumin (BSA) (New England Biolabs) in NEBuffer 4. pBABEpuro was
dephosphorylated with 0.5 U/1 µg of plasmid DNA of calf intestinal
alkaline phosphatase (CIP) (Finnzymes) for 1 h at 37 °C and
subsequently gel puriﬁed. Blunt end ligations of different POLGα
inserts to pBABEpuro were done in reactions that contained 300–
375 ng of insert, 30–75 ng of vector, 2000–3000 U of T4 DNA Ligase
and T4 DNA Ligase Reaction Buffer (New England Biolabs) with
polyethylene glycol (PEG) 8000 (Sigma). All reactions were
incubated at 15 °C overnight. Correct orientation of the insert was
veriﬁed by sequencing and PCR.4.7. Production of infectious pBABEpuro virus with human polymerase γ
complementary DNA insert
Retrovirus packaging cells of both GP+E86 and PA317 cell lines
were grown in D-MEM with 10% FBS (Gibco) and 1% L-Glutamate
(Invitrogen). Transfections of GP + E86 packaging cells with
pBABEpuro, + POLGα, + POLGα W748S,+ POLGα E1143G, or +
POLGα W748S+E1143G plasmids were done with Lipofectamine
2000 transfection reagent (Invitrogen) following manufacturer's
instructions. For transfection GP+E86 packaging cells were grown
to 90% conﬂuency and 4 h prior to transfection medium was changed.
Plasmid DNA and Lipofectamine reagent ratio in the transfection
was 1:3 and 20 µg of plasmid was used to transfect one 10 cm plate.
Transfected cells were passed 1:10 24–48 h after transfection
and after 48 h of transfection puromycin selection was started with
3 µg/ml of puromycin (Sigma). Subsequently, PA317 packaging cells
were infected with ﬁltered medium from transfected GP + E86 cells.
Transfected GP + E86 cells were passed to 50% conﬂuency 24 h prior
to collection of virus containing medium. Medium from GP + E86
cells was collected and ﬁltered through 0.45 µm syringe ﬁlter. PA317
cells were at 50% conﬂuency when 1 ml of ﬁltered virus containing
medium and 3 ml of D-MEM, 10% FBS, 1% L-Glutamate with 4 µg/ml
of polybrene (hexadimethrine bromide) (Sigma) was added to
them. PA317 cells were incubated in infectious polybrene containing
medium for 2 h at 37 °C in CO2-incubator after which 5 ml of D-MEM,
10% FBS, 1% L-Glutamate with 4 µg/ml of polybrene was added
to them. Incubation was continued for 5 h at 37 °C in CO2-incubator.
Infectious medium was removed and cells were washed once with
D-MEM. Infected cells were grown at 37 °C in CO2-incubator for 24 h
before starting puromycin selection with 3 µg/ml of puromycin that
was raised to 4 µg/ml after 24 h of selection.4.8. Transduction of target primary human ﬁbroblasts
Primary human ﬁbroblasts were transduced with virus containing
medium collected from PA317 cells as described above. Cells were
grown in D-MEM, 10% FBS, 1% L-Glutamate, 50 µg/ml uridine (Sigma),
2 µg/ml puromycin.
4.9. Protein expression analysis
Primary ﬁbroblasts were collected using trypsin (Invitrogen). Total
cellular RNA was extracted from cells with Qiagen RNeasy Mini Kit
(Qiagen). Total RNA (500 ng) and 0.25 µg of RandomPrimers (Promega)
in total volume of 15 µl were incubated for 5 min at 70 °C. Total RNA
(500 ng), previously incubated with 0.25 µg of random primers, was
reverse transcribed in 0.625 U of rRNasin inhibitor (Promega), 312.5 µM
of dNTP, and 200 U of M-MLV Reverse Transcriptase in 40 µl of its buffer
(M-MLV RT buffer) (Promega). Samples were incubated at 37 °C for 1 h.
Quantitative PCR reactions consisted of 83 pg of cDNA, TaqMan Gene
expression Assay mix, in ﬁnal concentrations of 45 nM of primers
and 12.5 nM TaqMan MGB probe in TaqMan Universal PCR Master
Mix (Applied Biosystems). In addition to the mRNA levels of transduced
POLGα, analyzed with assay on demand Hs00160298_m1, and its trans-
ducedmutant forms, TWINKLE expression levelswere alsomeasured and
analyzed using assay on demand Hs00222440_m1 for human TWINKLE.
Beta-actin gene ACTB was used as an internal control using assay on
demand Hs99999903_m1. Gene expression QPCRs were done in
separate tubes on MicroAmp Optical 96-well Reaction Plate (Applied
Biosystems) for each assay. PCR ampliﬁcation was done with ABI Prism
7000 quantitative PCR instrument and data was analyzedwith 7000 SDS
Sequence Detection Software version 1.2.3 (Applied Biosystems).
4.10. Mitochondrial DNA copy number analysis
MtDNA was quantiﬁed as described elsewhere [27].
4.11. Pulse labeling of mitochondrial translation products
In vitro labeling of mitochondrial translation was performed in
general as described elsewhere [32].
4.12. Three-dimensional modeling of the POLG-DNA complex
Docking of the template DNA onto the structure of the catalytic
subunit of POLG (PDB entry 3IKM, chain A) was performed using the
VMD software [24,33]. The structure of T7 DNA polymerase in com-
plex with DNA (PDB entry 1T8E [34]) was used for superposition of
the catalytic domains of the two enzymes.
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